Pulmonary
MultiCare Pulmonary Specialists is a multi-physician group located in Tacoma, WA. The site employs an experienced research team comprised of board certified Pulmonologists, Study Coordinators, and an Administrative Assistant. The site is conveniently located near three hospitals and all clinical research is done on site. In addition, the site has a comprehensive patient database that is connected to all MultiCare facilities.
Research Director:
James R. Taylor, M.D., Medical Director for the site, has over twenty (20) years of research experience and has conducted over 150 trials. Dr. Taylor trained at Stanford University, University of California San Francisco and the University of Washington. Dr. Taylor is board certified in Pulmonary, Critical Care and Internal Medicine, and is the Medical Director of the ICU at Tacoma General Hospital.
Principal Investigators:
James R. Taylor, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
Stephen C. Ryan, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Sub-Investigators:
Arthur R. Knodel, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Edward J. LeDoux, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Thomas N. Mann, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
John H. Rowlands, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Research Interests:
Research Director:
James R. Taylor, M.D., Medical Director for the site, has over twenty (20) years of research experience and has conducted over 150 trials. Dr. Taylor trained at Stanford University, University of California San Francisco and the University of Washington. Dr. Taylor is board certified in Pulmonary, Critical Care and Internal Medicine, and is the Medical Director of the ICU at Tacoma General Hospital.
Principal Investigators:
James R. Taylor, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
Stephen C. Ryan, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Sub-Investigators:
Arthur R. Knodel, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Edward J. LeDoux, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Thomas N. Mann, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care
John H. Rowlands, M.D., Board Certified Internal Medicine, Pulmonary, Critical Care, Sleep Medicine
Research Interests:
- Asthma
- Allergy & Allergic Rhinitis
- COPD
- Smoking Cessation
- Sleep Disorders
- Cystic Fibrosis
- Bronchiectasis
Pulmonary Studies Accepting Participants
- Adult - COPD Ehtos
- Study Number: PT010005-01—A randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with moderate to very severe COPD.
Study Info
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Kelly Mulligan, [email protected], 253-403-0389 - Adult - Boehringer Ingelheim COPD
- Study Number: Boehringer Ingelheim 1237.35 - A randomized, double-blind, active-controlled parallel group study to evaluate the impact of once daily treatment with orally inhaled tiotropium + olodaterol (5ug/5ug) fixed dose combination compared with tiotropium (5ug) on long term outcomes in patients with chronic obstructive pulmonary disease (COPD) and moderate (GOLD stage ll) lung function impairment.
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Smith, [email protected], 253-403-0389 - Adult - PT009002 COPD
- Study Number: PT009002-00—A randomized, double-blind, parallel group, multicenter study to assess the efficacy and safety of PT009 compared to PT005, PT008, and open-label Symbicort® Turbuhaler®, as an active control, on lung function over a 24-week treatment period in subjects with moderate to very severe COPD.
Study Info
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Kelly Mulligan, [email protected], 253-403-0389 - Adult - Terranova COPD
- Study Number: TERRANOVA—A randomized, double-blind, double dummy, 56-week placebo-controlled, multicenter, parallel group, Phase III study evaluating efficacy/safety of 3 Benralizumab doses in patients with moderate to very severe COPD with
previous exacerbations.
Study Info
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Jami Smith, [email protected], 253-403-0389 - Adult - Mereo COPD
- Study Number: MEREO—A Phase II, two-part, randomized, multi-center, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care for the treatment of acute
respiratory exacerbations of chronic obstructive pulmonary disease requiring hospitalization in adults.
Study Info
Principal Investigator(s): Stephen Ryan, MD
Study Coordinator: Kelly Mulligan, [email protected], 253-403-0389
